Health Care & Life Sciences » Pharmaceuticals | TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
3,598.00
7,904.00
3,449.00
8,755.00
3,000
Cost of Goods Sold (COGS) incl. D&A
7.00
-
-
-
-
-
Gross Income
7.00
-
-
-
-
-
SG&A Expense
7,553.00
9,762.00
31,320.00
29,331.00
26,917.00
37,712
EBIT
7,560.00
6,179.00
23,467.00
25,976.00
18,210.00
34,740
Unusual Expense
118.00
37.00
65.00
-
-
-
Non Operating Income/Expense
-
-
45.00
87.00
7.00
12
Interest Expense
30.00
667.00
923.00
1,119.00
886.00
231
Pretax Income
7,708.00
6,809.00
24,410.00
27,008.00
19,103.00
34,959
Consolidated Net Income
7,956.00
7,106.00
24,441.00
27,008.00
19,103.00
34,959
Net Income
7,956.00
7,106.00
24,441.00
27,008.00
19,103.00
34,959
Net Income After Extraordinaries
7,956.00
7,106.00
24,441.00
27,008.00
19,103.00
34,959
Net Income Available to Common
7,956.00
7,106.00
24,441.00
27,008.00
19,103.00
34,959
EPS (Basic)
0.63
4.40
2.20
2.13
1.14
1.30
Basic Shares Outstanding
12,632.80
1,615.00
11,115.70
12,677.90
16,806.10
26,945.70
EPS (Diluted)
0.63
4.40
2.20
2.13
1.14
1.30
Diluted Shares Outstanding
12,632.80
1,615.00
11,115.70
12,677.90
16,806.10
26,945.70
EBITDA
7,553.00
6,164.00
23,416.00
25,882.00
18,162.00
34,712
Other After Tax Income (Expense)
248.00
297.00
31.00
-
-
-

About TRACON Pharmaceuticals

View Profile
Address
4350 La Jolla Village Drive
San Diego California 92122
United States
Employees -
Website http://www.traconpharma.com
Updated 07/08/2019
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.